Els Van Valckenborgh
Overview
Explore the profile of Els Van Valckenborgh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
2087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitt T, Delnord M, Cauet E, Van Valckenborgh E, Van Den Bulcke M
J Health Organ Manag
. 2025 Mar;
PMID: 40045482
Purpose: Precision medicine, also known as personalized medicine, enables the provision of tailored health services to patients. In the prevention, early detection, and treatment of cancers, precision medicine is highly...
2.
McCrary J, Van Valckenborgh E, Poirel H, de Putter R, van Rooij J, Horgan D, et al.
Eur J Public Health
. 2024 Jun;
34(4):666-675.
PMID: 38905592
Background: Somatic and germline genetic alterations are significant drivers of cancer. Increasing integration of new technologies which profile these alterations requires timely, equitable and high-quality genetic counselling to facilitate accurate...
3.
Schmitt T, Delnord M, Cauet E, Van Valckenborgh E, Van Den Bulcke M
Eur J Public Health
. 2024 Mar;
34(4):624-631.
PMID: 38547501
Background: Precision medicine represents a paradigm shift in health systems, moving from a one-size-fits-all approach to a more individualized form of care, spanning multiple scientific disciplines including drug discovery, genomics,...
4.
Delnord M, Van Valckenborgh E, Hebrant A, Antoniou A, Van Hoof W, Waeytens A, et al.
Semin Cancer Biol
. 2021 Jun;
84:255-262.
PMID: 34129914
Rationale: In 2016, Belgium launched the Next Generation Sequencing (NGS) Roadbook, consisting in 10 Actions, across the health care system, to facilitate the uptake of NGS in routine clinical practice....
5.
Delcourt T, Vanneste K, Rida Soumali M, Coucke W, Ghislain V, Hebrant A, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33138022
Next-generation sequencing (NGS) is being integrated into routine clinical practice in the field of (hemato-) oncology to search for variants with diagnostic, prognostic, or therapeutic value at potentially low allelic...
6.
Froyen G, Mercier M, Lierman E, Vandepoele K, Nollet F, Boone E, et al.
Cancers (Basel)
. 2020 Jan;
11(12).
PMID: 31888289
In most diagnostic laboratories, targeted next-generation sequencing (NGS) is currently the default assay for the detection of somatic variants in solid as well as haematological tumours. Independent of the method,...
7.
Maes A, Maes K, De Raeve H, De Smedt E, Vlummens P, Szablewski V, et al.
Br J Cancer
. 2019 May;
120(12):1137-1146.
PMID: 31089208
Background: The aggressive B-cell non-Hodgkin lymphomas diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are characterised by a high proliferation rate. The anaphase-promoting complex/cyclosome (APC/C) and its co-activators...
8.
de Veirman K, Menu E, Maes K, De Beule N, De Smedt E, Maes A, et al.
Cancer Lett
. 2018 Nov;
442:233-241.
PMID: 30419344
Multiple Myeloma (MM) is an incurable malignancy of terminally differentiated plasma cells, which are predominantly localized in the bone marrow. Myeloid-derived suppressor cells (MDSC) are described to promote MM progression...
9.
Van Valckenborgh E, Hebrant A, Antoniou A, Van Hoof W, Van Bussel J, Pauwels P, et al.
Arch Public Health
. 2018 Sep;
76:49.
PMID: 30202522
In the field of oncology research, next-generation sequencing has contributed significantly to the discovery of DNA mutations associated with diagnosis and prognosis. It also aids in the development of targeted...
10.
de Veirman K, De Beule N, Maes K, Menu E, de Bruyne E, De Raeve H, et al.
Cancer Immunol Res
. 2017 Sep;
5(10):839-846.
PMID: 28903971
Dysregulated expression of S100 protein family members is associated with cancer proliferation, invasion, angiogenesis, and inflammation. S100A9 induces myeloid-derived suppressor cell (MDSC) accumulation and activity. MDSCs, immunosuppressive cells that contribute...